New Clinical Data, Patient Reported Outcomes, Real-World Utilization, and Comparative-Effectiveness Models to be Featured in Four Oral and One Poster Presentation
PRINCETON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced new data further defining the potential of mogamulizumab in the treatment of relapsed or refractory mycosis fungoides and Sézary syndrome, two subtypes of cutaneous T-cell lymphoma, will be featured at the World Congress of Cutaneous Lymphomas (WCCL) in Montréal, Canada.
Drawing on complementary evidence streams, including patient-reported outcomes, comparative-effectiveness estimates, molecular biomarker signals, and real-world utilization, these analyses collectively provide a more complete understanding of the therapeutic profile and potential of mogamulizumab.